Cardiovascular prognosis in patients with type 2 diabetes: Contribution of heart and kidney subclinical damage

American Heart Journal

Volumn 169, Issue 1, 2015, Pages 108-114.e7

  Sosner, Philippe ^a,b,c   Hulin Delmotte, Charlotte ^a,b   Saulnier, Pierre Jean ^a,b,d   Cabasson, Séverin ^a   Gand, Elise ^a   Torremocha, Florence ^a   Piguel, Xavier ^a,e   Miot, Aurélie ^a,b   Maréchaud, Richard ^a,b   Herpin, Daniel ^a,b   Ragot, Stéphanie ^a,b,d   Hadjadj, Samy ^a,b,d,i   Duengler, Frédérique ^e   Labbé, Louis ^e   Demer, Cécile ^e   Brishoual, Sonia ^a   Mauco, Gérard ^f   Bridoux, Frank ^g   Manic, Helene ^h   Ducrocq, Gregory ^e   Llaty, Pierre ^e   Montaigne, David ^e   Rigalleau, Vincent ^e   Roussel, Ronan ^e   Zaoui, Philippe ^e   Limousi, Frederike ^e   more..

^a POITIERS UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE POITIERS   (France)

^c Sports Medicine Centre MON STADE   (France)

^d INSERM   (France)

^e Faculté de Médecine et de Pharmacie ^*

^f Cardiology   (France)

^g Nephrology Internal Medicine Unit   (France)

^h Ophthalmology   (France)

ⁱ Endocrinology and Metabolic Diseases   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIABETIC PATIENT; ELECTROCARDIOGRAM; ELECTROCARDIOGRAPHY; FEMALE; FRAMINGHAM RISK SCORE; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; KIDNEY INJURY; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; ALBUMINURIA; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHIES; HYPERTROPHY, LEFT VENTRICULAR; MORTALITY; RISK FACTOR; URINE;

ALBUMINURIA; CARDIOVASCULAR DISEASES; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; ELECTROCARDIOGRAPHY; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; MALE; PROGNOSIS; RISK FACTORS;

EID: 84925883899     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.09.012     Document Type: Article

References (41)

1. Whiting DR, Guariguata L, Weil C, et al. IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract 2011;94:311-21.
2. de Simone G, Parati G. Imaging techniques for non-invasive assessment of coronary heart disease in hypertension: value of an integrated approach. J Hypertens 2001;19:679-82.
3. Frohlich ED, Apstein C, Chobanian AV, et al. The heart in hypertension. N Engl J Med 1992;327:998-1008.
4. Levy D, Salomon M, D'Agostino RB, et al. Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994;90: 1786-93.
5. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med 1969;71:89-105.
6. Vakili BA, Okin PM, Devereux RB. Prognostic implications of left ventricular hypertrophy. Am Heart J 2001;141:334-41.
7. Townsend JC. Increased albumin excretion in diabetes. J Clin Pathol 1990;43:3-8.
8. Mogensen CE, Chachati A, Christensen CK, et al. Microalbuminuria: an early marker of renal involvement in diabetes. Uremia Invest 1985;9:85-95.
9. Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-305.
10. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998;97:1837-47.
11. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701.
12. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998;352:837-53.
13. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-72.
14. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56). Clin Sci (Lond) 2001;101:671-9.
15. Kothari V, Stevens RJ, Adler AI, et al. UKPDS 60: risk of stroke in type 2 diabetes estimated by the UK Prospective Diabetes Study risk engine. Stroke 2002;33:1776-81.
16. Kengne AP, Patel A, Marre M, et al. Contemporary model for cardiovascular risk prediction in people with type 2 diabetes. Eur J Cardiovasc Prev Rehabil 2011;18:393-8.
17. Hadjadj S, Fumeron F, Roussel R, et al. Prognostic value of the insertion/ deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-insulin-dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular Events, and Ramipril (DIABHYCAR), Diabete de type 2, Nephropathie et Genetique (DIAB2NEPHROGENE), and Survie, Diabete de type 2 et Genetique (SURDIAGENE) studies. Diabetes Care 2008;31:1847-52.
18. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949;37:161-86.
19. Gubner RS, Ungerleider HE. Electrocardiographic criteria of left ventricular hypertrophy. Arch Intern Med 1943;72:196-209.
20. Molloy TJ, Okin PM, Devereux RB, et al. Electrocardiographic detection of left ventricular hypertrophy by the simple QRS voltage-duration product. J Am Coll Cardiol 1992;20:1180-6.
21. Levey AS, Coresh J, Balk E, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003;139:137-47.
22. Halimi JM, Hadjadj S, Aboyans V, et al. Microalbuminuria and urinary albumin excretion: French clinical practice guidelines. Diabetes Metab 2007;33:303-9.
23. Greenland P, Smith Jr SC, Grundy SM. Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests. Circulation 2001;104:1863-7.
24. Pencina MJ, D'Agostino Sr RB, D'Agostino Jr RB, et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-72.
25. Bruno G, Giunti S, Bargero G, et al. Sex-differences in prevalence of electrocardiographic left ventricular hypertrophy in type 2 diabetes: the Casale Monferrato Study. Diabet Med 2004;21:823-8.
26. Cea-Calvo L, Conthe P, Gomez-Fernandez P, et al. Target organ damage and cardiovascular complications in patients with hypertension and type 2 diabetes in Spain: a cross-sectional study. Cardiovasc Diabetol 2006;5:23.
27. Okin PM, Devereux RB, Jern S, et al. Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: the Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. Hypertension 2000;36:766-73.
28. Bruno G, Cavallo-Perin P, Bargero G, et al. Prevalence and risk factors for micro-and macroalbuminuria in an Italian population-based cohort of NIDDM subjects. Diabetes Care 1996;19: 43-7.
29. Robles NR, Felix FJ, Fernandez-Berges D, et al. Prevalence of abnormal urinary albumin excretion in a population-based study in Spain: results from the HERMEX Study. Eur J Clin Invest 2012;42: 1272-7.
30. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9.
31. Kannel WB, Abbott RD. A prognostic comparison of asymptomatic left ventricular hypertrophy and unrecognized myocardial infarction: the Framingham Study. Am Heart J 1986;111:391-7.
32. Ishikawa J, Ishikawa S, Kabutoya T, et al. Cornell product left ventricular hypertrophy in electrocardiogram and the risk of stroke in a general population. Hypertension 2009;53:28-34.
33. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421-6.
34. Ninomiya T, Perkovic V, de Galan BE, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20:1813-21.
35. Fox CS, Matsushita K, Woodward M, et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012;380:1662-73.
36. Schunkert H, Jackson B, Tang SS, et al. Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. Circulation 1993;87:1328-39.
37. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, et al. Albuminuria reflects widespread vascular damage. Steno Hypotheses Diabetol 1989;32:219-26.
38. de Zeeuw D, Parving HH, Henning RH. Microalbuminuria as an early marker for cardiovascular disease. J Am Soc Nephrol 2006;17: 2100-5.
39. Leoncini G, Ratto E, Viazzi F, et al. Increased ambulatory arterial stiffness index is associated with target organ damage in primary hypertension. Hypertension 2006;48:397-403.
40. Ishimura E, Taniwaki H, Tsuchida T, et al. Urinary albumin excretion associated with arterial wall stiffness rather than thickness in type 2 diabetic patients. J Nephrol 2007;20:204-11.
41. Chau NP, Bouhanick B, Mestivier D, et al. Normal and abnormal day-to-day variability of urinary albumin excretion in control and diabetic subjects. Diabetes Metab 2000;26:36-41.